<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Symptom-based management of amyotrophic lateral sclerosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Symptom-based management of amyotrophic lateral sclerosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Symptom-based management of amyotrophic lateral sclerosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Nestor Galvez-Jimenez, MD, MSc, MHSA, FACP
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Colin Quinn, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jeremy M Shefner, MD, PhD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            R Sean Morrison, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard P Goddeau, Jr, DO, FAHA
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 05, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder that causes muscle weakness, disability, and eventually death, with a median survival of three to five years. Symptomatic management is the mainstay of treatment for ALS and is reviewed in this topic.
        </p>
        <p>
         Other aspects of ALS are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5156.html" rel="external">
          "Epidemiology and pathogenesis of amyotrophic lateral sclerosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5136.html" rel="external">
          "Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5138.html" rel="external">
          "Diagnosis of amyotrophic lateral sclerosis and other forms of motor neuron disease"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5128.html" rel="external">
          "Disease-modifying treatment of amyotrophic lateral sclerosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         ALS is a progressive neurodegenerative disorder. Most ALS patients die within three to five years of diagnosis. However, longer survival is not rare. Approximately 30 percent of ALS patients are alive five years after diagnosis, and 10 to 20 percent survive for greater than 10 years. Factors associated with more favorable survival without respiratory failure include a younger age at symptom onset, longer delay from symptom onset to diagnosis, higher ALS functional rating scale score and forced vital capacity at presentation, and limb rather than bulbar symptom onset [
         <a href="#rid1">
          1-6
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          BREAKING THE NEWS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Informing the patient and family of the diagnosis of ALS is a daunting task for the clinician. The diagnosis should always be given face to face, with enough time to ensure the patient and family do not feel rushed [
         <a href="#rid7">
          7,8
         </a>
         ]. It may be helpful to have the patient's support network present; European guidelines note a perceived advantage if the patient's network outnumbers the medical staff present at the meeting [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
         The initial encounter should be one of support and hope. It is important to give a warning that bad news is coming and to acknowledge and explore the patient's reaction. Allow for questions, offer support, and emphasize non-abandonment. Offer a second opinion if the patient wishes. It is often useful to schedule a return visit within a short time frame so that questions can be addressed and family members can attend if desired. (See
         <a class="medical medical_review" href="/z/d/html/83706.html" rel="external">
          "Communication of prognosis in palliative care"
         </a>
         .)
        </p>
        <p>
         Many patients have a delay in diagnosis that is very distressing. For these patients, a diagnosis may be good news, in that uncertainty is reduced and active therapy can be initiated. The discussion of diagnosis should always be accompanied by a discussion of the ways that symptoms can be treated as well as by institution of disease-modifying treatment, assuming cost is not prohibitive. (See
         <a class="medical medical_review" href="/z/d/html/5128.html" rel="external">
          "Disease-modifying treatment of amyotrophic lateral sclerosis", section on 'Riluzole'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          MULTIDISCIPLINARY CARE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Multidisciplinary ALS clinics provide care from neurologists, physical therapists, occupational therapists, speech therapists, respiratory therapists, dietitians, social workers, and nursing care managers [
         <a href="#rid8">
          8-12
         </a>
         ]. Thus, specialized clinics can guide the management of the complex issues related to ALS, which include respiratory symptoms, nutrition, dysarthria, dysphagia, functional decline, and psychosocial problems.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Multidisciplinary ALS clinics
         </strong>
         – Although data are limited, some [
         <a href="#rid13">
          13,14
         </a>
         ] but not all [
         <a href="#rid15">
          15
         </a>
         ] studies suggest that patients with ALS who are followed by multidisciplinary or tertiary ALS centers have improved survival compared with those who are followed by general neurology clinics. In addition, multidisciplinary care may improve quality of life [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Current American guidelines state that specialized multidisciplinary clinic referral should be considered for patients with ALS, with the goals of optimizing health care delivery, prolonging survival, and enhancing quality of life [
         <a href="#rid9">
          9
         </a>
         ]. Similarly, European guidelines note that multidisciplinary care should be available for all people affected by ALS [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Palliative care
         </strong>
         – ALS is a chronic disease, and early integration of palliative care can provide an added layer of support to help address progressive disability, symptom burdens, and family/caregiver stressors [
         <a href="#rid16">
          16,17
         </a>
         ]. Palliative care aims to enhance quality of life in all stages of a serious illness and does not have to be limited to end-of-life care. Comprehensive palliative support includes establishing goals of care that are in keeping with the patient's values and preferences; consistent and sustained communication between the patient and all caregivers; psychosocial, spiritual, and practical support to both patients and their family; and coordination across sites of care. Early evidence suggests specialty palliative care services may be successfully integrated into ALS care and are associated with improved quality of life and a reduction in intensive care unit days and length of hospitalization [
         <a href="#rid18">
          18-20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hospice care
         </strong>
         – At the end of life (expected prognosis of six months or less) or when goals shift exclusively to comfort, hospice should become involved [
         <a href="#rid7">
          7,11,17,21
         </a>
         ]. A discussion of advance directives should be initiated well in advance of the terminal phase and revisited at least every six months. The clinician should play an active role in helping patients and family members find resources in the community, and the clinician should also encourage the enlistment of a social worker.
        </p>
        <p>
        </p>
        <p>
         Information for health care practitioners and patients regarding ALS management is available from the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.als.org%2F&amp;token=%2BCjrhIBVW0jZK35njTvgcViMg5o2XoQRQ67yQ8CO%2B2g%3D&amp;TOPIC_ID=5129" target="_blank">
          ALS Association
         </a>
         and the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.mda.org%2F&amp;token=5yLNPmHjkOhvnhOBCCm6DE7VGu9ZZuQdpEWXw3mRscA%3D&amp;TOPIC_ID=5129" target="_blank">
          Muscular Dystrophy Association
         </a>
         . Both organizations certify clinics that have met a variety of quality and access criteria.
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          RESPIRATORY FUNCTION MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Our suggested management of respiratory symptoms in patients with ALS is based upon the available published data, consensus guidelines [
         <a href="#rid7">
          7,8,22,23
         </a>
         ], and clinical experience. Important aspects of pulmonary care include counseling the patient and family about potential treatments, the use of pulmonary tests to assess respiratory function, and the utility of noninvasive and invasive ventilation [
         <a href="#rid24">
          24
         </a>
         ]. The general aspects of respiratory management in patients with neuromuscular disease are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/5121.html" rel="external">
          "Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5124.html" rel="external">
          "Respiratory muscle weakness due to neuromuscular disease: Management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Counseling
         </span>
         <span class="headingEndMark">
          —
         </span>
         At the time of initial diagnosis, discussion should focus on limited aspects of diagnosis and potential treatments. A discussion of respiratory options may be deferred at this visit if the patient has no respiratory symptoms and has a vital capacity (VC) &gt;60 percent of predicted for age and height. However, respiratory management should be a topic of careful discussion very early in the course of a clinician's relationship with the patient.
        </p>
        <p>
         Once beyond initial diagnosis but before respiratory symptoms occur, it is crucial to inform patients of the respiratory choices available to them and the need for their participation in the decision-making process. Decisions about late issues, such as the desire for tracheostomy and chronic ventilatory support, must be considered as part of a patient's overall care plan. Advance care planning should begin early and focus on what things matter most to patients. By understanding goals and values, clinicians can help guide patients through particular treatment decisions that arise.
        </p>
        <p>
         At all stages of the disease, patients have the right to refuse or withdraw any treatment, including mechanical ventilation. When withdrawing ventilation, opioids and anxiolytics should be used in adequate doses to relieve dyspnea and anxiety. (See
         <a class="medical medical_review" href="/z/d/html/16295.html" rel="external">
          "Withholding and withdrawing ventilatory support in adults in the intensive care unit"
         </a>
         .)
        </p>
        <p>
         It is important to offer patients information about the terminal stage of ALS and provide information to patients at any point in the disease course when they are ready. This is especially important once dyspnea or nocturnal hypoventilation begins or when the VC drops below 50 percent. Most patients will benefit from noninvasive ventilation at this point in disease. Patients may fear "choking to death," and describing the terminal hypercapnic coma and resulting peaceful death can provide relief from this fear in most patients and families [
         <a href="#rid21">
          21,25
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Pulmonary tests
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with ALS should have serial assessment of respiratory function every three months starting at the time of diagnosis. Understanding of the pace of an individual's disease is very helpful for planning appropriate interventions at the right time. Risk factors for earlier progression of respiratory dysfunction include bulbar-onset disease, short time from symptom onset to diagnosis, and lower baseline ALS functional rating scale score and forced VC [
         <a href="#rid5">
          5,6
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Vital capacity
         </strong>
         – A decrease of VC to 25 percent of predicted is often associated with respiratory symptoms, and a VC of &lt;25 to 30 percent of predicted is associated with significant risk of respiratory failure or sudden death [
         <a href="#rid26">
          26,27
         </a>
         ]. Hypoxia and hypercarbia are late findings and thus should
         <strong>
          not
         </strong>
         be relied upon as early predictors of the need for mechanical ventilation or other forms of respiratory support [
         <a href="#rid28">
          28
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5121.html" rel="external">
          "Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6969.html" rel="external">
          "Overview of pulmonary function testing in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Although widely used, the VC is not an ideal test of respiratory muscle strength in patients with ALS, in part because the shape of the lung pressure volume curve makes the VC insensitive to modest changes in muscle strength [
         <a href="#rid29">
          29
         </a>
         ]. In addition, patients with ALS and bulbar weakness may not have enough strength to make a complete seal around the mouthpiece, particularly in later stages of disease progression. This potentially limits the clinical utility of the VC at a time when prognostic information is most urgently needed regarding initiation of noninvasive ventilation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Maximal sniff inspiratory force
         </strong>
         – Another alternative, the maximal sniff nasal inspiratory force (SNIF; also called the sniff nasal pressure), avoids the need for a mouthpiece and thus may be better suited than the VC and MIP for testing patients with bulbar weakness. In addition, the SNIF has been shown to correlate well with diaphragm strength [
         <a href="#rid30">
          30
         </a>
         ], and it is sensitive to changes in respiratory muscle strength [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a prospective observational study of 98 patients with ALS, a higher proportion of patients could still perform the SNIF at the last clinic visit (before death or study completion) compared with the VC or MIP (94 versus 84 versus 79 percent) [
         <a href="#rid32">
          32
         </a>
         ]. In this study, a SNIF of &lt;40 cm H
         <sub>
          2
         </sub>
         O had a higher sensitivity for predicting six-month mortality compared with a VC of &lt;50 percent maximum (97 versus 58 percent) but a slightly lower specificity (79 versus 96 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         These results support the impression that the SNIF test is clinically useful for monitoring respiratory muscle strength in patients with ALS. However, the prognostic value of the SNIF requires confirmation in larger clinical studies.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Others
         </strong>
         – Other pulmonary function tests that may be used to monitor respiratory status in ALS include the maximal inspiratory pressure (MIP) and overnight oximetry. The MIP may have similar limitations as VC, as patients with bulbar weakness may be unable to perform the test accurately due to difficulty forming a complete seal around the testing mouthpiece. Overnight oximetry is an alternative approach, using peripheral monitoring of blood oxygenation, typically in the home setting, to assess for changes in minute ventilation during sleep. In a study of 476 patients with ALS monitored with serial respiratory testing, neuromuscular respiratory weakness was identified earlier by MIP and overnight oximetry than VC testing (median of 1.5 and 1.6 versus 3.8 years from disease onset) [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Noninvasive positive pressure ventilation
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest the use of noninvasive positive pressure ventilation (NPPV) for patients with ALS and respiratory insufficiency [
         <a href="#rid22">
          22
         </a>
         ]. Criteria for initiating noninvasive ventilation include VC &lt;50 percent of predicted, or the presence of orthopnea, or SNIF &lt;40 cm, or MIP &lt;-60 cm, or abnormal nocturnal oximetry. These criteria are most commonly employed at ALS centers and are recommended by guidelines [
         <a href="#rid22">
          22,23
         </a>
         ].
        </p>
        <p>
         NPPV is the evidence-based standard of care for patients with ALS and respiratory insufficiency [
         <a href="#rid8">
          8,24,34
         </a>
         ]. Noninvasive ventilation is associated with improved survival and quality of life [
         <a href="#rid22">
          22,35-37
         </a>
         ]. It is especially useful if patients have symptoms of respiratory compromise at night, but patients often use it during waking hours as the disease progresses. The development of portable ventilators with volume-targeted pressure support have enhanced noninvasive respiratory support options for patients with ALS, particularly in those compliant with ≥4 hours of NPPV each day [
         <a href="#rid38">
          38
         </a>
         ] and those without severe bulbar dysfunction [
         <a href="#rid35">
          35,36,38
         </a>
         ]. A retrospective cohort study found that NPPV was associated with improved survival even in patients with bulbar-onset ALS [
         <a href="#rid39">
          39
         </a>
         ], although this result is inconsistent with some other reports.
        </p>
        <p>
         As adjustment to NPPV requires time and patience on the part of respiratory therapists and patients, it should be initiated as early as possible in patients with respiratory compromise.
        </p>
        <p>
         Patient tolerance of the face mask used is crucial to the success of NPPV. There are many face masks to choose from [
         <a href="#rid24">
          24
         </a>
         ], and patients must be encouraged not to forgo treatment if they are not comfortable with the initial interface. Occasionally, small doses of anxiolytic medications will help with the adjustment as well.
        </p>
        <p>
         The use of NPPV is not a substitute for permanent assisted ventilation, and careful decision-making regarding desire for tracheostomy and permanent ventilation must be ongoing, whether or not NPPV is employed [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Invasive mechanical ventilation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Though there is significant variability, mean survival with invasive mechanical ventilation (IMV) is estimated at approximately 30 months [
         <a href="#rid20">
          20
         </a>
         ]. In a cross-sectional analysis on the impact of different symptom-specific treatments in German patients with ALS, tracheostomy was associated with an improved quality of life [
         <a href="#rid37">
          37
         </a>
         ]. However, caregiver satisfaction was lower in patients on IMV. When long-term survival is the goal, tracheostomy and IMV should be considered and discussed carefully with attention to the full burdens and benefits of this treatment. Discussions should also include the option to stop the ventilation at any time [
         <a href="#rid40">
          40
         </a>
         ]. Since the disease will progress despite IMV, discussions should also include patient preferences regarding future withdrawal of IMV. Some patients may, for example, express a wish for ventilation to be withdrawn in the future if they reach a "locked-in state" (unable to communicate) or develop severe dementia. For patients who choose to stop invasive ventilation, symptoms of dyspnea, anxiety, and distress should be anticipated and treated. (See
         <a class="local">
          'Dyspnea'
         </a>
         below.)
        </p>
        <p>
         For most patients in the United States, the demands of invasive ventilation are difficult or impossible to manage at home, and nursing home placement results. Rates of IMV use in ALS vary greatly among countries, with estimated rates of 4 percent in the United States, 10 percent in Italy, and 29 to 38 percent in Japan [
         <a href="#rid41">
          41,42
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Immunizations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Current infectious disease guidelines recommend annual seasonal influenza vaccination for individuals with neurologic conditions that can potentially compromise the handling of respiratory secretions. (See
         <a class="medical medical_review" href="/z/d/html/7007.html" rel="external">
          "Seasonal influenza vaccination in adults"
         </a>
         .)
        </p>
        <p>
         In addition, the pneumococcal vaccine is recommended for all individuals with chronic pulmonary conditions. (See
         <a class="medical medical_review" href="/z/d/html/7021.html" rel="external">
          "Pneumococcal vaccination in adults"
         </a>
         .)
        </p>
        <p>
         Therefore, patients with ALS should be treated with pneumococcal vaccination and annual seasonal influenza vaccination.
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h1">
          MANAGEMENT OF SWALLOWING AND NUTRITION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Weight loss is common in ALS and may be due to dysphagia, poor appetite, or difficulty self-feeding due to arm weakness. Dysphagia increases the risk for insufficient caloric and fluid intake and worsening of weakness and fatigue [
         <a href="#rid7">
          7,21
         </a>
         ]. It also increases the risk for aspiration and choking. Many ALS patients with feeding tubes may still be able to eat small amounts of a modified diet by mouth.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Anorexia
         </strong>
         – For patients with reduced appetite but preserved swallowing function, the first step is to determine if anorexia is due to a mood disorder. Cognitive impairment and mood disorders are common in patients with ALS. (See
         <a class="local">
          'Cognitive impairment'
         </a>
         below and
         <a class="local">
          'Psychosocial aspects'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients with primary anorexia, medications may be offered to help stimulate the appetite.
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          Olanzapine
         </a>
         may be used based on efficacy among patients with cancer or anorexia nervosa. Other agents, including stimulants such as
         <a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">
          mirtazapine
         </a>
         , megestrol, and glucocorticoids, have been used, but evidence of their efficacy is limited. (See
         <a class="medical medical_review" href="/z/d/html/2816.html" rel="external">
          "Management of cancer anorexia/cachexia", section on 'Pharmacologic treatments'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14743.html" rel="external">
          "Anorexia nervosa in adults: Pharmacotherapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dysphagia
         </strong>
         – Initial management of dysphagia includes modification of food and fluid consistency. (See
         <a class="medical medical_review" href="/z/d/html/95508.html" rel="external">
          "Swallowing disorders and aspiration in palliative care: Assessment and strategies for management", section on 'Alterations in food and liquid texture and consistency'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients with dysphagia that does not respond to or worsens despite modifications in food consistency, we pursue additional strategies. We suggest PEG placement for patients with ALS with normal to moderately impaired respiratory function who have symptomatic dysphagia. We particularly focus on patients for whom eating has become a burden rather than a source of enjoyment.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         PEG placement should first be discussed with the patient and family members. It is best to enlist a speech-language pathologist and nutritionist early in the treatment when potential decisions about long-term feeding and hydration are entertained. (See
         <a class="medical medical_review" href="/z/d/html/95508.html" rel="external">
          "Swallowing disorders and aspiration in palliative care: Assessment and strategies for management", section on 'Artificial nutrition and hydration'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2568.html" rel="external">
          "Gastrostomy tubes: Uses, patient selection, and efficacy in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For optimal safety and efficacy, PEG should be placed before the vital capacity (VC) falls to 50 percent of predicted and not in the preterminal phase, even if symptomatic dysphagia is not present at that time [
         <a href="#rid22">
          22
         </a>
         ]. This recommendation is based on the increased morbidity of the procedure as respiratory function declines.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The effect of gastrostomy tubes on survival and quality of life has been examined in multiple studies with mixed results [
         <a href="#rid43">
          43-46
         </a>
         ]. A causal inference analysis from 2017 found a negative effect on survival and no improvement in quality of life in patients undergoing gastric tube placement [
         <a href="#rid45">
          45
         </a>
         ]. In contrast, a 2019 meta-analysis demonstrated a 6-month survival benefit in patients undergoing gastrostomy, with greater benefit seen in patients who had preserved respiratory function. Mood and functional status were not significantly improved [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a preliminary randomized controlled trial of 24 patients with ALS already receiving percutaneous nutrition, there were fewer adverse events, including death, over the course of the trial (four months) and subsequent follow-up (five months) in patients assigned to a high-carbohydrate, hypercaloric diet compared with those assigned to a high-fat, hypercaloric diet or an isocaloric diet [
         <a href="#rid47">
          47
         </a>
         ]. These results suggest, but do not establish, that the high-carbohydrate, hypercaloric enteral diet is safe. However, they do
         <strong>
          not
         </strong>
         provide evidence of efficacy regarding improvement in survival or other patient-important outcomes, given the small number of subjects with relatively advanced disease who were studied. A larger placebo-controlled trial in 201 patients with ALS found no improvement in survival with an oral high-calorie and fat-supplemented diet, although post hoc analysis suggested a possible effect in fast-progressing patients [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h1">
          MANAGEMENT OF OTHER ASSOCIATED SYMPTOMS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Among the prominent symptoms of ALS addressed by national guidelines are dyspnea, muscle spasm, spasticity, sialorrhea, and pseudobulbar affect [
         <a href="#rid7">
          7-9,49
         </a>
         ].
        </p>
        <p>
         Equally important and potentially debilitating are other problems associated with ALS. These include dysarthria, muscle weakness, functional decline, loss of ambulation, pain, sleep problems, and psychosocial issues such as depression. These issues have not been addressed systematically by high-quality randomized controlled trials [
         <a href="#rid9">
          9,22,50
         </a>
         ]. Where no guideline recommendations are available, the suggestions listed here are largely based upon clinical experience and other expert reviews [
         <a href="#rid11">
          11,21,25
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Dysarthria and communication
         </span>
         <span class="headingEndMark">
          —
         </span>
         The progression of muscle weakness may make speech increasingly difficult and ultimately impossible. Speech therapy is rarely helpful; however, communication disorders specialists are important resources to help with choosing appropriate alternative communication methods. These methods may include writing with pen and paper or alphabet boards. Electronic assistive communication devices, which can be adapted for use with either hand or eye controls, may improve quality of life for patients and caregivers and should be offered early in the disease course [
         <a href="#rid51">
          51,52
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Dyspnea
         </span>
         <span class="headingEndMark">
          —
         </span>
         Early symptoms of respiratory insufficiency include orthopnea, morning headache, daytime fatigue, and dyspnea on exertion. First-line treatment is noninvasive ventilation for patients who tolerate it. Providing adequate relief for dyspnea and anxiety is paramount, as these are two of the most prevalent and unpleasant symptoms in the terminal phase [
         <a href="#rid7">
          7
         </a>
         ]. However, there are no controlled studies evaluating the treatment of dyspnea in ALS [
         <a href="#rid9">
          9
         </a>
         ]. The suggested approach is as follows.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The use of noninvasive positive pressure ventilation (NPPV) may ameliorate dyspnea. (See
         <a class="local">
          'Noninvasive positive pressure ventilation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Identify and treat reversible causes of dyspnea such as bronchospasm and pneumonia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         General supportive measures to treat dyspnea include relaxation techniques and psychosocial support, modification in activity level, and use of a fan with cool air blowing on the face. Trunk elevation, chest physiotherapy, and reassurance may be helpful. (See
         <a class="medical medical_review" href="/z/d/html/14238.html" rel="external">
          "Assessment and management of dyspnea in palliative care", section on 'Management of anxiety'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For distressing dyspnea, systemic opioids are useful as second-line treatment when symptoms persist despite NPPV or if NPPV is not tolerated. Dosing is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/14238.html" rel="external">
          "Assessment and management of dyspnea in palliative care", section on 'Opioids'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with dyspnea that is refractory to opioids or accompanied by anxiety, benzodiazepines may be a useful adjunctive therapy. This may be especially needed in the terminal phases of ALS. However, the evidence does not support a role for benzodiazepines as a routine management strategy for dyspnea in the absence of anxiety. (See
         <a class="medical medical_review" href="/z/d/html/14238.html" rel="external">
          "Assessment and management of dyspnea in palliative care", section on 'Management of anxiety'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients in the last days and hours of life with dyspnea, pain, or agitated delirium, palliative sedation with nonopioid drugs, including benzodiazepines, barbiturates, and
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         , can be used to control refractory symptoms. (See
         <a class="medical medical_review" href="/z/d/html/83710.html" rel="external">
          "Palliative sedation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Oxygen therapy is not recommended for the treatment of dyspnea in ALS except in some cases during the active dying process. Supplemental oxygen may worsen hypocapnia, particularly in patients not receiving noninvasive ventilation. (See
         <a class="medical medical_review" href="/z/d/html/14238.html" rel="external">
          "Assessment and management of dyspnea in palliative care", section on 'Oxygen'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h2">
          Fatigue
         </span>
         <span class="headingEndMark">
          —
         </span>
         Fatigue is among the most common symptoms of ALS and reported in approximately 90 percent of patients [
         <a href="#rid53">
          53
         </a>
         ]. Few controlled studies have addressed the pharmacologic treatment of fatigue in ALS [
         <a href="#rid9">
          9,54
         </a>
         ]. Fatigue due to hypoventilation may improve with noninvasive ventilation. Fatigue is occasionally associated with
         <a class="drug drug_general" data-topicid="9865" href="/z/d/drug information/9865.html" rel="external">
          riluzole
         </a>
         treatment but more commonly is a manifestation of the effort required to perform daily activities. The results of a small controlled trial suggest that
         <a class="drug drug_general" data-topicid="10157" href="/z/d/drug information/10157.html" rel="external">
          modafinil
         </a>
         is sometimes helpful for fatigue [
         <a href="#rid55">
          55
         </a>
         ]. Permanent or temporary withdrawal of riluzole may be considered in patients with debilitating fatigue [
         <a href="#rid9">
          9
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5128.html" rel="external">
          "Disease-modifying treatment of amyotrophic lateral sclerosis", section on 'Riluzole'
         </a>
         .)
        </p>
        <p>
         Other treatment options for fatigue include glucocorticoids (eg, a two-week trial of
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         8 mg daily) and
         <a class="drug drug_general" data-topicid="9603" href="/z/d/drug information/9603.html" rel="external">
          megestrol acetate
         </a>
         (400 to 800 mg daily). (See
         <a class="medical medical_review" href="/z/d/html/14239.html" rel="external">
          "Overview of fatigue in palliative care", section on 'Pharmacologic approaches'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h2">
          Muscle spasms
         </span>
         <span class="headingEndMark">
          —
         </span>
         Muscle spasms or cramps can cause severe pain and discomfort. Nonpharmacologic treatments such as stretching and massage can be helpful.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9648" href="/z/d/drug information/9648.html" rel="external">
          Mexiletine
         </a>
         , a sodium channel blocking antiarrhythmic drug, is an option in patients with frequent and painful cramps. Mexiletine was shown to be safe and was noted to have dose-dependent positive effects on muscle cramps in a subset of patients enrolled in a 12-week randomized trial that failed to show a benefit on ALS disease progression compared with placebo [
         <a href="#rid56">
          56
         </a>
         ]. A follow-up trial of mexiletine 150 mg twice daily in 20 patients with ALS and muscle cramps found that mexiletine decreased mean daily cramp frequency by approximately two cramps per day compared with placebo (from a mean baseline of six cramps per day) [
         <a href="#rid57">
          57
         </a>
         ]. There were no serious adverse events or QT interval changes over the two-week treatment period, and the drug was well tolerated at the prescribed dose of 300 mg per day; one patient discontinued the study due to dizziness. Patients with heart disease, baseline electrocardiogram abnormalities, or liver disease were excluded. A higher dose of 900 mg per day was not well tolerated in the earlier trial [
         <a href="#rid56">
          56
         </a>
         ]. In addition to dizziness, other common dose-related side effects include nausea, tremor, and falls. Gradual dose titration may improve tolerability.
        </p>
        <p>
         Previously,
         <a class="drug drug_general" data-topicid="9847" href="/z/d/drug information/9847.html" rel="external">
          quinine
         </a>
         sulfate 325 mg twice a day was considered the most effective treatment option for muscle cramps [
         <a href="#rid21">
          21
         </a>
         ]. However, the US Food and Drug Administration restricted the use of quinine sulfate in the United States to the treatment of malaria falciparum because of concerns regarding severe adverse events, including cardiac arrhythmias, thrombocytopenia, and severe hypersensitivity reactions, as well as potentially serious drug interactions associated with quinine [
         <a href="#rid58">
          58
         </a>
         ].
        </p>
        <p>
         Other treatment options for muscle spasms or cramps include
         <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">
          levetiracetam
         </a>
         [
         <a href="#rid59">
          59
         </a>
         ],
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         , and
         <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">
          phenytoin
         </a>
         [
         <a href="#rid8">
          8
         </a>
         ]. Other medications that have been tried for cramps include
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         ,
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          gabapentin
         </a>
         , and
         <a class="drug drug_general" data-topicid="9999" href="/z/d/drug information/9999.html" rel="external">
          tizanidine
         </a>
         , but their utility is quite limited.
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h2">
          Spasticity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Spastic muscle tone may be useful to help patients maintain antigravity power as muscle weakness progresses. However, excess spasticity can be uncomfortable and negatively impact coordination, ambulation, dressing, and other activities of daily living. In such cases, an oral antispasticity drug (eg,
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         ,
         <a class="drug drug_general" data-topicid="9999" href="/z/d/drug information/9999.html" rel="external">
          tizanidine
         </a>
         ) is generally indicated as a first-line symptomatic option [
         <a href="#rid21">
          21
         </a>
         ]. Botulinum neurotoxin (BoNT) injections can be useful when oral therapy is not effective or well tolerated. Baclofen pumps may be useful in a subset of patients with severe spasticity of the lower extremities that does not improve with adequate doses of antispasticity medications.
        </p>
        <p>
         There are few data regarding pharmacotherapy for spasticity in ALS [
         <a href="#rid9">
          9
         </a>
         ]. A systematic review found no high-quality randomized controlled trials evaluating treatments for spasticity in ALS/motor neuron disease [
         <a href="#rid60">
          60
         </a>
         ]. Nevertheless, the available studies in other neurologic conditions suggest that
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         and
         <a class="drug drug_general" data-topicid="9999" href="/z/d/drug information/9999.html" rel="external">
          tizanidine
         </a>
         are roughly equivalent in efficacy as antispasticity drugs and have similar rates of adverse events [
         <a href="#rid61">
          61
         </a>
         ]. In the author's experience, baclofen tends to be better tolerated and more effective than tizanidine; for both drugs, weakness and drowsiness are often dose limiting. Combinations of more than one antispasticity drug are poorly tolerated in patients with ALS due to excess weakness.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          Baclofen
         </a>
         can be started at 5 mg two to three times daily. The total dose can be titrated up as necessary in three- to seven-day increments as tolerated. Titration can be slowed if side effects develop and stopped once an effective dose is reached. The usual maximum daily dose is 80 mg, although total daily doses up to 120 mg per day may be needed, depending on response and tolerance. Except in patients with a primary lateral sclerosis phenotype, a baclofen pump is usually not considered.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9999" href="/z/d/drug information/9999.html" rel="external">
          Tizanidine
         </a>
         can be started at 2 to 4 mg by mouth twice daily. The total dose can be titrated up as necessary in three- to seven-day increments as tolerated. In the author's experience, total doses above 24 mg daily do not offer additional benefit and are not well tolerated in patients with ALS. Weakness, fatigue, and drowsiness tend to be dose limiting at higher doses.
        </p>
        <p>
        </p>
        <p>
         For patients who do not tolerate or benefit from an oral antispasticity drug, botulinum toxin injections are an option. Limited experience suggests that BoNT (
         <a class="drug drug_general" data-topicid="15586" href="/z/d/drug information/15586.html" rel="external">
          incobotulinumtoxinA
         </a>
         ) combined with physical therapy is safe in patients with ALS and improves tone and clinical function at three months [
         <a href="#rid62">
          62
         </a>
         ].
        </p>
        <p>
         Preliminary data suggest that cannabinoids may have modest effects on spasticity and pain, although further studies are needed to understand whether effects are clinically meaningful. In a randomized trial in 59 patients with ALS,
         <a class="drug drug_general" data-topicid="9457" href="/z/d/drug information/9457.html" rel="external">
          nabiximols
         </a>
         , an oromucosal cannabidiol/tetrahydrocannabinol spray available in some countries outside the United States, improved spasticity scores on a 5-point scale compared with placebo (mean difference 0.32 points) and was well tolerated over a six-week treatment period [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h2">
          Muscle weakness and functional decline
         </span>
         <span class="headingEndMark">
          —
         </span>
         Progressive muscle weakness and functional decline are hallmarks of ALS. Efforts must be made to help patients compensate for this nearly inevitable progression [
         <a href="#rid21">
          21,34
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Assistive devices such as canes, ankle foot orthoses, crutches, and walking frames can be helpful early in the course of the disease and may improve quality of life [
         <a href="#rid37">
          37
         </a>
         ]. Most patients will eventually require a wheelchair.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Higher toilet seats and bathtub lifts help to maintain toileting and bathing independence.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Removable headrests can help with the loss of head control that occurs with neck muscle weakness.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Specialized eating utensils, grips, and holders can be useful.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A pressure-relieving mattress of air or high-density foam, along with proper positioning and repositioning, may help to prevent the development of pressure ulcers. (See
         <a class="medical medical_review" href="/z/d/html/2885.html" rel="external">
          "Prevention of pressure-induced skin and soft tissue injury"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Limited data suggest that stretching and strengthening exercises are not harmful and may be associated with functional benefit for patients with ALS [
         <a href="#rid34">
          34,64,65
         </a>
         ], but larger studies are needed to confirm these preliminary findings.
        </p>
        <p class="headingAnchor" id="H690158188">
         <span class="h2">
          Sialorrhea
         </span>
         <span class="headingEndMark">
          —
         </span>
         Drooling is a common symptom in ALS [
         <a href="#rid9">
          9
         </a>
         ]. It is caused by the combination of facial muscle weakness and reduced swallowing ability (pseudohypersalivation). The clinician must distinguish between sialorrhea and thick mucus production because treatment of these symptoms differs [
         <a href="#rid7">
          7
         </a>
         ]. (See
         <a class="local">
          'Thick mucus'
         </a>
         below.)
        </p>
        <p>
         First-line therapy involves anticholinergic medications such as [
         <a href="#rid8">
          8,9
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          Atropine
         </a>
         0.4 mg every four to six hours.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8545" href="/z/d/drug information/8545.html" rel="external">
          Hyoscyamine
         </a>
         is available in several formulations, including sustained release (0.375 to 0.75 mg every 12 hours; maximum 1.5 mg per 24 hours), fast-acting oral (0.125 to 0.25 mg every four hours or as needed before meals or food; maximum 1.5 mg per 24 hours), and transdermal (one or two patches every three days).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">
          Amitriptyline
         </a>
         10 to 150 mg once daily at bed time.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8496" href="/z/d/drug information/8496.html" rel="external">
          Glycopyrrolate
         </a>
         1 mg three times daily.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9915" href="/z/d/drug information/9915.html" rel="external">
          Scopolamine
         </a>
         transdermal, one patch (1.5 mg) applied behind the ear. After three days, remove the old patch and replace with new patch behind the other ear.
        </p>
        <p>
        </p>
        <p>
         If these medications are not effective or tolerated, the following procedures may be used:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Botulinum toxin injection into the salivary glands appears to be safe and useful for treating sialorrhea in patients with ALS, as demonstrated in preliminary studies [
         <a href="#rid66">
          66-69
         </a>
         ] and in a small randomized controlled trial of botulinum toxin type B (
         <a class="drug drug_general" data-topicid="9155" href="/z/d/drug information/9155.html" rel="external">
          rimabotulinumtoxinB
         </a>
         ) [
         <a href="#rid70">
          70-72
         </a>
         ]. However, botulinum toxin injection should be used cautiously as it has been associated with prolonged dysphagia in patients who have Machado-Joseph disease with bulbar involvement, dystonia, and parkinsonism [
         <a href="#rid73">
          73
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6230.html" rel="external">
          "Autosomal dominant spinocerebellar ataxias", section on 'SCA3 (Machado-Joseph disease)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Low-dose radiation therapy to the salivary glands is suggested if sialorrhea does not improve with pharmacologic therapy [
         <a href="#rid8">
          8,9,49,74-76
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h2">
          Thick mucus
         </span>
         <span class="headingEndMark">
          —
         </span>
         Thick mucus production associated with sialorrhea and increased oropharyngeal secretions can be treated in several ways [
         <a href="#rid8">
          8,22,24
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increased fluid intake
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mucolytic (eg,
         <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">
          acetylcysteine
         </a>
         200 to 400 mg three times daily) if sufficient cough flow is present
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Humidification of air
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cough augmentation with respiratory therapy
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cough augmentation with mechanical insufflation-exsufflation devices (see
         <a class="medical medical_review" href="/z/d/html/5124.html" rel="external">
          "Respiratory muscle weakness due to neuromuscular disease: Management", section on 'Mechanical insufflation-exsufflation'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h2">
          Pain
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pain in ALS can arise from a variety of causes that include reduced mobility, muscle spasms or cramps, spasticity, and comorbid conditions. Reduced mobility can cause musculoskeletal pain as well as pressure-induced skin and soft tissue injury [
         <a href="#rid77">
          77
         </a>
         ].
        </p>
        <p>
         There is little high-quality evidence concerning the management of pain in ALS [
         <a href="#rid78">
          78
         </a>
         ]. Attentive nursing care is important, since frequent changes in position can help prevent skin breakdown and joint stiffness in patients with reduced mobility [
         <a href="#rid79">
          79
         </a>
         ]. Assistive devices such as special mattresses, pillows, and custom-fitted wheelchairs may also help to prevent pain [
         <a href="#rid80">
          80
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2885.html" rel="external">
          "Prevention of pressure-induced skin and soft tissue injury"
         </a>
         .)
        </p>
        <p>
         Additional management options include [
         <a href="#rid21">
          21,80
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Treatment of muscle spasticity and spasms (see
         <a class="local">
          'Spasticity'
         </a>
         above and
         <a class="local">
          'Muscle spasms'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nonopioid analgesics and antiinflammatory drugs
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Opioids can be used liberally when nonopioid analgesics fail
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h2">
          Pseudobulbar affect
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pseudobulbar affect (PBA; also called emotional lability, emotional incontinence, or pathological laughing and crying [PLC]) is a term that describes sudden uncontrollable outbursts of laughter or tearfulness that occur in many patients with ALS as the disease progresses [
         <a href="#rid81">
          81
         </a>
         ]. The pathology underlying PBA is not well understood but may be due to impairment of descending corticobulbar input and/or cerebellar modulation controlling emotional expression [
         <a href="#rid82">
          82-84
         </a>
         ]. Although its prevalence is unknown, limited retrospective data suggest that pseudobulbar palsy may affect close to 50 percent of patients with ALS (though not all affected need treatment for it), and it is more common in those with the bulbar form [
         <a href="#rid85">
          85
         </a>
         ]. Patients should be counseled that the symptoms of pseudobulbar affect do not reflect a psychological disorder. (See
         <a class="medical medical_review" href="/z/d/html/5136.html" rel="external">
          "Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease"
         </a>
         .)
        </p>
        <p>
         Treatment options for pseudobulbar affect include [
         <a href="#rid86">
          86
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The combination drug
         <a class="drug drug_general" data-topicid="16087" href="/z/d/drug information/16087.html" rel="external">
          dextromethorphan-quinidine
         </a>
         (20 mg/10 mg); the recommended starting dose is one capsule once daily for seven days then increase to one capsule twice daily with periodic reassessment to determine if continued use is necessary.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tricyclic antidepressants such as
         <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">
          amitriptyline
         </a>
         10 to 150 mg at bedtime [
         <a href="#rid87">
          87
         </a>
         ]; the starting dose is 10 to 25 mg at bedtime, and dosing is increased slowly as needed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Selective serotonin reuptake inhibitors such as
         <a class="drug drug_general" data-topicid="8474" href="/z/d/drug information/8474.html" rel="external">
          fluvoxamine
         </a>
         100 to 200 mg daily [
         <a href="#rid88">
          88
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         A controlled trial of 140 subjects with ALS found that twice-daily treatment with a combination of
         <a class="drug drug_general" data-topicid="8893" href="/z/d/drug information/8893.html" rel="external">
          dextromethorphan
         </a>
         and
         <a class="drug drug_general" data-topicid="9846" href="/z/d/drug information/9846.html" rel="external">
          quinidine
         </a>
         (30 mg/30 mg) was effective for reducing the frequency and severity of pathologic laughter and crying compared with either drug alone [
         <a href="#rid89">
          89
         </a>
         ]. Treatment was also associated with an improvement in quality of life. Adverse events were described as mostly mild or moderate and included nausea, dizziness, and gastrointestinal complaints. However, treatment-related discontinuation for the combination was 24 percent during the four-week duration of the trial compared with 6 percent for dextromethorphan and 8 percent for quinidine. However, another trial using two formulations with lower dose quinidine in the combination drug
         <a class="drug drug_general" data-topicid="16087" href="/z/d/drug information/16087.html" rel="external">
          dextromethorphan-quinidine
         </a>
         (30 mg/10 mg or 20 mg/10 mg) reported reduction of PBA episodes and lower discontinuation rates than observed for the higher dose formulation evaluated in the earlier trial [
         <a href="#rid90">
          90
         </a>
         ]. On the basis of efficacy data, dextromethorphan-quinidine was approved for treatment of PBA in 2010 [
         <a href="#rid91">
          91
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8893" href="/z/d/drug information/8893.html" rel="external">
          Dextromethorphan
         </a>
         is a weak N-methyl-D-aspartate (NMDA) receptor antagonist, and it is proposed to act as an agonist at the sigma 1 receptor [
         <a href="#rid92">
          92,93
         </a>
         ]. However, its mechanism of action for treating pseudobulbar palsy is unknown. In approximately 90 percent of people, dextromethorphan is rapidly metabolized by the cytochrome P450 2D6 enzyme (CYP2D6) [
         <a href="#rid94">
          94,95
         </a>
         ], and
         <a class="drug drug_general" data-topicid="9846" href="/z/d/drug information/9846.html" rel="external">
          quinidine
         </a>
         is a selective CYP2D6 inhibitor [
         <a href="#rid96">
          96
         </a>
         ]. Thus, the coadministration of quinidine reduces the metabolism and maintains serum plasma levels.
        </p>
        <p>
         Neither
         <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">
          amitriptyline
         </a>
         nor
         <a class="drug drug_general" data-topicid="8474" href="/z/d/drug information/8474.html" rel="external">
          fluvoxamine
         </a>
         has been studied for the treatment of pseudobulbar palsy in controlled trials. However, the results of several small, placebo-controlled, randomized trials involving patients with stroke suggest that some aspects of pseudobulbar affect respond to treatment with antidepressants, including
         <a class="drug drug_general" data-topicid="9711" href="/z/d/drug information/9711.html" rel="external">
          nortriptyline
         </a>
         ,
         <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">
          sertraline
         </a>
         , and
         <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">
          fluoxetine
         </a>
         [
         <a href="#rid86">
          86,97,98
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2301722690">
         <span class="h2">
          Cognitive impairment
         </span>
         <span class="headingEndMark">
          —
         </span>
         ALS is associated with an increased incidence of frontotemporal dementia (FTD). FTD is a form of dementia characterized by symptoms of apathy, difficulties planning and organizing (executive function), and often either behavioral disturbances or language impairment. Since many patients develop severe dysarthria and impaired motor function affecting ability to write from ALS, it is sometimes difficult to fully assess cognitive function in advanced ALS. It is estimated that up to 30 percent of ALS patients have cognitive impairments in executive function not meeting criteria for dementia [
         <a href="#rid99">
          99,100
         </a>
         ], and up to 15 percent meet criteria for FTD. (See
         <a class="medical medical_review" href="/z/d/html/14139.html" rel="external">
          "Frontotemporal dementia: Treatment"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h2">
          Psychosocial aspects
         </span>
         <span class="headingEndMark">
          —
         </span>
         Quality of life in patients with ALS appears to be more dependent on psychological and existential factors than physical factors such as strength or physical function [
         <a href="#rid101">
          101,102
         </a>
         ]. Depression and hopelessness are thought to be common in patients with ALS. In a meta-analysis of 46 studies, the pooled prevalence of depression among patients with ALS was 34 percent but varied by severity and assessment tool used [
         <a href="#rid103">
          103
         </a>
         ]. In a cohort of over 900 patients, the prevalence of moderate depression assessed by patient questionnaire was 33 percent [
         <a href="#rid104">
          104
         </a>
         ], while prevalence estimates acquired from structured interviews of patients with ALS range from 5 to 15 percent [
         <a href="#rid105">
          105
         </a>
         ]. Nonetheless, these rates are higher than the 9 percent prevalence rate reported for current depression in the general population [
         <a href="#rid106">
          106
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1722.html" rel="external">
          "Unipolar depression in adults: Epidemiology", section on 'Prevalence'
         </a>
         .)
        </p>
        <p>
         The presence of depression does not appear to be associated with a desire to hasten dying in patients with end-stage ALS [
         <a href="#rid107">
          107
         </a>
         ]. However, initial depression has been associated with shorter survival time [
         <a href="#rid104">
          104
         </a>
         ].
        </p>
        <p>
         Observational data suggest that treatment of depression can improve quality of life in ALS, even in physically debilitated patients [
         <a href="#rid108">
          108
         </a>
         ]. However, there are no controlled trials evaluating the treatment of depression in ALS [
         <a href="#rid8">
          8,9
         </a>
         ].
        </p>
        <p>
         It may be useful to try a tricyclic antidepressant such as
         <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">
          amitriptyline
         </a>
         , since it also treats other symptoms of ALS such as drooling, pseudobulbar affect, and insomnia. Selective serotonin reuptake inhibitors may also be used, particularly if side effects of tricyclics are poorly tolerated. (See
         <a class="medical medical_review" href="/z/d/html/1725.html" rel="external">
          "Unipolar major depression in adults: Choosing initial treatment"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h2">
          Sleep problems
         </span>
         <span class="headingEndMark">
          —
         </span>
         Sleep difficulty is often secondary to other problems associated with ALS. These include anxiety, depression, dysphagia, and dyspnea; inability to change posture during sleep because of weakness, muscle cramps, and fasciculations contributes to this as well [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The first step is to identify and treat underlying causes.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nocturnal oximetry or polysomnography can identify patients with oxygen desaturation who might benefit from noninvasive intermittent ventilation or NPPV [
         <a href="#rid109">
          109
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sedatives should be used sparingly. While there are no trials evaluating the treatment of insomnia in ALS, suggested choices at bedtime include
         <a class="drug drug_general" data-topicid="10057" href="/z/d/drug information/10057.html" rel="external">
          zolpidem
         </a>
         5 to 10 mg,
         <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">
          amitriptyline
         </a>
         10 to 150 mg,
         <a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">
          mirtazapine
         </a>
         15 to 45 mg,
         <a class="drug drug_general" data-topicid="9239" href="/z/d/drug information/9239.html" rel="external">
          chloral hydrate
         </a>
         250 to 500 mg,
         <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">
          diphenhydramine
         </a>
         25 to 50 mg, and
         <a class="drug drug_general" data-topicid="8469" href="/z/d/drug information/8469.html" rel="external">
          flurazepam
         </a>
         15 to 30 mg [
         <a href="#rid8">
          8
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/97868.html" rel="external">
          "Pharmacotherapy for insomnia in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H893551056">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/118906.html" rel="external">
          "Society guideline links: Motor neuron disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1119454760">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/86016.html" rel="external">
          "Patient education: Amyotrophic lateral sclerosis (ALS) (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3046472531">
         <span class="h1">
          PATIENT PERSPECTIVE TOPIC
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patient perspectives are provided for selected disorders to help clinicians better understand the patient experience and patient concerns. These narratives may offer insights into patient values and preferences not included in other UpToDate topics. (See
         <a class="medical medical_review" href="/z/d/html/139137.html" rel="external">
          "Patient perspective: Amyotrophic lateral sclerosis (ALS)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H27">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognosis and the role of multidisciplinary care
         </strong>
         – Most patients with amyotrophic lateral sclerosis (ALS) die within three to five years of diagnosis. However, longer survival is not rare. Patients who receive multidisciplinary care at specialized ALS clinics appear to have improved survival compared with those who are followed by general neurology clinics. Palliative care should be provided at the time of diagnosis. Palliative care aims to relieve suffering in all stages of disease and does not have to be limited to end-of-life care. As ALS progresses and the expected prognosis is six months or less or when goals shift exclusively to comfort, hospice should become involved. (See
         <a class="local">
          'Prognosis'
         </a>
         above and
         <a class="local">
          'Multidisciplinary care'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management of respiratory symptoms
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Counseling
         </strong>
         – Before respiratory symptoms occur in ALS, it is crucial to inform patients of both the available respiratory management choices and the need for their participation in the decision-making process. At all stages of the disease, patients have the right to refuse or withdraw any treatment. (See
         <a class="local">
          'Counseling'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Serial assessments of pulmonary function
         </strong>
         – For all patients with ALS, we suggest serial assessment of pulmonary function every three months starting at the time of diagnosis. Useful measures include the vital capacity (VC), maximal inspiratory pressure (MIP), and maximal sniff nasal inspiratory force (SNIF). The SNIF avoids the need for a mouthpiece and thus may be better suited than the VC or MIP for testing patients with bulbar weakness. (See
         <a class="local">
          'Pulmonary tests'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Ventilatory support for respiratory compromise
         </strong>
         – For patients with ALS and respiratory insufficiency, we suggest the use of noninvasive positive pressure ventilation (NPPV) (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). Suggested criteria for when to initiate NPPV are as follows (see
         <a class="local">
          'Noninvasive positive pressure ventilation'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         VC &lt;50 percent of predicted, or
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Presence of orthopnea, or
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         SNIF &lt;40 cm, or
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         MIP &lt;-60 cm, or
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Abnormal nocturnal oximetry
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         When long-term survival is the goal, invasive mechanical ventilation (IMV) is an option. (See
         <a class="local">
          'Invasive mechanical ventilation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Immunizations
         </strong>
         – Patients with ALS should be treated with pneumococcal vaccination and annual seasonal influenza vaccination. (See
         <a class="local">
          'Immunizations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Percutaneous gastrostomy tube placement for dysphagia
         </strong>
         – For willing patients with ALS who have symptomatic dysphagia, we suggest percutaneous gastrostomy tube (PEG) placement (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). For optimal safety, PEG should be placed before the VC falls to ≤50 percent of predicted. (See
         <a class="local">
          'Management of swallowing and nutrition'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Symptomatic management
         </strong>
         – Additional prominent symptoms of ALS may benefit from specific interventions. These include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Dysarthria
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Dyspnea
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Muscle spasms
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Muscle spasticity
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Muscle weakness and functional decline
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Sialorrhea
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Fatigue
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Thick mucus
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Pain
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Pseudobulbar affect
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Cognitive impairment, including frontotemporal dementia (FTD)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Psychosocial aspects
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Sleep problems
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         However, there are few controlled trials evaluating these issues in patients with ALS. Thus, most recommendations are based upon clinical experience and expert consensus. (See
         <a class="local">
          'Management of other associated symptoms'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Eisen A, Schulzer M, MacNeil M, et al. Duration of amyotrophic lateral sclerosis is age dependent. Muscle Nerve 1993; 16:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jablecki CK, Berry C, Leach J. Survival prediction in amyotrophic lateral sclerosis. Muscle Nerve 1989; 12:833.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strong MJ, Hudson AJ, Alvord WG. Familial amyotrophic lateral sclerosis, 1850-1989: a statistical analysis of the world literature. Can J Neurol Sci 1991; 18:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Westeneng HJ, Debray TPA, Visser AE, et al. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol 2018; 17:423.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ackrivo J, Hansen-Flaschen J, Wileyto EP, et al. Development of a prognostic model of respiratory insufficiency or death in amyotrophic lateral sclerosis. Eur Respir J 2019; 53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ackrivo J, Hansen-Flaschen J, Jones BL, et al. Classifying Patients with Amyotrophic Lateral Sclerosis by Changes in FVC. A Group-based Trajectory Analysis. Am J Respir Crit Care Med 2019; 200:1513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller RG, Rosenberg JA, Gelinas DF, et al. Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology: ALS Practice Parameters Task Force. Neurology 1999; 52:1311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis:, Andersen PM, Abrahams S, et al. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)--revised report of an EFNS task force. Eur J Neurol 2012; 19:360.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2009; 73:1227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van den Berg JP, Kalmijn S, Lindeman E, et al. Multidisciplinary ALS care improves quality of life in patients with ALS. Neurology 2005; 65:1264.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mitsumoto H, Rabkin JG. Palliative care for patients with amyotrophic lateral sclerosis: "prepare for the worst and hope for the best". JAMA 2007; 298:207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rooney J, Byrne S, Heverin M, et al. A multidisciplinary clinic approach improves survival in ALS: a comparative study of ALS in Ireland and Northern Ireland. J Neurol Neurosurg Psychiatry 2015; 86:496.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chiò A, Bottacchi E, Buffa C, et al. Positive effects of tertiary centres for amyotrophic lateral sclerosis on outcome and use of hospital facilities. J Neurol Neurosurg Psychiatry 2006; 77:948.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Traynor BJ, Alexander M, Corr B, et al. Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study, 1996-2000. J Neurol Neurosurg Psychiatry 2003; 74:1258.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zoccolella S, Beghi E, Palagano G, et al. ALS multidisciplinary clinic and survival. Results from a population-based study in Southern Italy. J Neurol 2007; 254:1107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oliver DJ, Borasio GD, Caraceni A, et al. A consensus review on the development of palliative care for patients with chronic and progressive neurological disease. Eur J Neurol 2016; 23:30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sethi A, Everett E, Mehta A, et al. The Role of Specialty Palliative Care for Amyotrophic Lateral Sclerosis. Am J Hosp Palliat Care 2022; 39:865.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brizzi K, Paganoni S, Zehm A, et al. Integration of a palliative care specialist in an amyotrophic lateral sclerosis clinic: Observations from one center. Muscle Nerve 2019; 60:137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zwicker J, Qureshi D, Talarico R, et al. Dying of amyotrophic lateral sclerosis: Health care use and cost in the last year of life. Neurology 2019; 93:e2083.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Veronese S, Gallo G, Valle A, et al. Specialist palliative care improves the quality of life in advanced neurodegenerative disorders: NE-PAL, a pilot randomised controlled study. BMJ Support Palliat Care 2017; 7:164.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borasio GD, Voltz R, Miller RG. Palliative care in amyotrophic lateral sclerosis. Neurol Clin 2001; 19:829.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2009; 73:1218.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khan A, Frazer-Green L, Amin R, et al. Respiratory Management of Patients With Neuromuscular Weakness: An American College of Chest Physicians Clinical Practice Guideline and Expert Panel Report. Chest 2023; 164:394.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gruis KL, Lechtzin N. Respiratory therapies for amyotrophic lateral sclerosis: a primer. Muscle Nerve 2012; 46:313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borasio GD, Miller RG. Clinical characteristics and management of ALS. Semin Neurol 2001; 21:155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greene-Chandos D, Torbey M. Critical Care of Neuromuscular Disorders. Continuum (Minneap Minn) 2018; 24:1753.
          </a>
         </li>
         <li class="breakAll">
          Schiffman PL. Pulmonary function and respiratory management of ALS. In: Amyotrophic Lateral Sclerosis: Diagnosis and Management for the Clinician, Belsh JM, Schiffman PL (Eds), Futura, 1996. p.333.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rabinstein AA, Wijdicks EF. Warning signs of imminent respiratory failure in neurological patients. Semin Neurol 2003; 23:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fitting JW, Paillex R, Hirt L, et al. Sniff nasal pressure: a sensitive respiratory test to assess progression of amyotrophic lateral sclerosis. Ann Neurol 1999; 46:887.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lyall RA, Donaldson N, Polkey MI, et al. Respiratory muscle strength and ventilatory failure in amyotrophic lateral sclerosis. Brain 2001; 124:2000.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stefanutti D, Benoist MR, Scheinmann P, et al. Usefulness of sniff nasal pressure in patients with neuromuscular or skeletal disorders. Am J Respir Crit Care Med 2000; 162:1507.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morgan RK, McNally S, Alexander M, et al. Use of Sniff nasal-inspiratory force to predict survival in amyotrophic lateral sclerosis. Am J Respir Crit Care Med 2005; 171:269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kelly CR, Parra-Cantu C, Thapa P, et al. Comparative Performance of Different Respiratory Test Parameters for Detection of Early Respiratory Insufficiency in Patients With ALS. Neurology 2022; 99:e743.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karam CY, Paganoni S, Joyce N, et al. Palliative Care Issues in Amyotrophic Lateral Sclerosis: An Evidenced-Based Review. Am J Hosp Palliat Care 2016; 33:84.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bourke SC, Tomlinson M, Williams TL, et al. Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial. Lancet Neurol 2006; 5:140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Radunovic A, Annane D, Rafiq MK, et al. Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev 2017; 10:CD004427.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peseschkian T, Cordts I, Günther R, et al. A Nation-Wide, Multi-Center Study on the Quality of Life of ALS Patients in Germany. Brain Sci 2021; 11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lo Coco D, Marchese S, Pesco MC, et al. Noninvasive positive-pressure ventilation in ALS: predictors of tolerance and survival. Neurology 2006; 67:761.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berlowitz DJ, Howard ME, Fiore JF Jr, et al. Identifying who will benefit from non-invasive ventilation in amyotrophic lateral sclerosis/motor neurone disease in a clinical cohort. J Neurol Neurosurg Psychiatry 2016; 87:280.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Faull C, Oliver D. Withdrawal of ventilation at the request of a patient with motor neurone disease: guidance for professionals. BMJ Support Palliat Care 2016; 6:144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takei K, Tsuda K, Takahashi F, et al. An assessment of treatment guidelines, clinical practices, demographics, and progression of disease among patients with amyotrophic lateral sclerosis in Japan, the United States, and Europe. Amyotroph Lateral Scler Frontotemporal Degener 2017; 18:88.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chiò A, Calvo A, Ghiglione P, et al. Tracheostomy in amyotrophic lateral sclerosis: a 10-year population-based study in Italy. J Neurol Neurosurg Psychiatry 2010; 81:1141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zamietra K, Lehman EB, Felgoise SH, et al. Non-invasive ventilation and gastrostomy may not impact overall quality of life in patients with ALS. Amyotroph Lateral Scler 2012; 13:55.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Körner S, Hendricks M, Kollewe K, et al. Weight loss, dysphagia and supplement intake in patients with amyotrophic lateral sclerosis (ALS): impact on quality of life and therapeutic options. BMC Neurol 2013; 13:84.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McDonnell E, Schoenfeld D, Paganoni S, Atassi N. Causal inference methods to study gastric tube use in amyotrophic lateral sclerosis. Neurology 2017; 89:1483.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bond L, Ganguly P, Khamankar N, et al. A Comprehensive Examination of Percutaneous Endoscopic Gastrostomy and Its Association with Amyotrophic Lateral Sclerosis Patient Outcomes. Brain Sci 2019; 9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wills AM, Hubbard J, Macklin EA, et al. Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet 2014; 383:2065.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ludolph AC, Dorst J, Dreyhaupt J, et al. Effect of High-Caloric Nutrition on Survival in Amyotrophic Lateral Sclerosis. Ann Neurol 2020; 87:206.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andersen PM, Borasio GD, Dengler R, et al. Good practice in the management of amyotrophic lateral sclerosis: clinical guidelines. An evidence-based review with good practice points. EALSC Working Group. Amyotroph Lateral Scler 2007; 8:195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ng L, Khan F, Young CA, Galea M. Symptomatic treatments for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev 2017; 1:CD011776.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Körner S, Sieniawski M, Kollewe K, et al. Speech therapy and communication device: impact on quality of life and mood in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 2013; 14:20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Londral A, Pinto A, Pinto S, et al. Quality of life in amyotrophic lateral sclerosis patients and caregivers: Impact of assistive communication from early stages. Muscle Nerve 2015; 52:933.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nicholson K, Murphy A, McDonnell E, et al. Improving symptom management for people with amyotrophic lateral sclerosis. Muscle Nerve 2018; 57:20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gibbons C, Pagnini F, Friede T, Young CA. Treatment of fatigue in amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev 2018; 1:CD011005.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rabkin JG, Gordon PH, McElhiney M, et al. Modafinil treatment of fatigue in patients with ALS: a placebo-controlled study. Muscle Nerve 2009; 39:297.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weiss MD, Macklin EA, Simmons Z, et al. A randomized trial of mexiletine in ALS: Safety and effects on muscle cramps and progression. Neurology 2016; 86:1474.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oskarsson B, Moore D, Mozaffar T, et al. Mexiletine for muscle cramps in amyotrophic lateral sclerosis: A randomized, double-blind crossover trial. Muscle Nerve 2018.
          </a>
         </li>
         <li class="breakAll">
          US Food and Drug Administration. FDA advances effort against marketed unapproved drugs. FDA orders unapproved quinine drugs from the market and cautions consumers about "off-label" use of quinine to treat leg cramps. www.fda.gov/bbs/topics/NEWS/2006/NEW01521.html (Accessed on March 23, 2009).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bedlack RS, Pastula DM, Hawes J, Heydt D. Open-label pilot trial of levetiracetam for cramps and spasticity in patients with motor neuron disease. Amyotroph Lateral Scler 2009; 10:210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ashworth NL, Satkunam LE, Deforge D. Treatment for spasticity in amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev 2012; :CD004156.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chou R, Peterson K, Helfand M. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. J Pain Symptom Manage 2004; 28:140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marvulli R, Megna M, Citraro A, et al. Botulinum Toxin Type A and Physiotherapy in Spasticity of the Lower Limbs Due to Amyotrophic Lateral Sclerosis. Toxins (Basel) 2019; 11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Riva N, Mora G, Sorarù G, et al. Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurol 2019; 18:155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dal Bello-Haas V, Florence JM. Therapeutic exercise for people with amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database Syst Rev 2013; :CD005229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shefner JM. Effects of Strength Training in Amyotrophic Lateral Sclerosis: How Much Do We Know? Muscle Nerve 2019; 59:6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giess R, Naumann M, Werner E, et al. Injections of botulinum toxin A into the salivary glands improve sialorrhoea in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2000; 69:121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lipp A, Trottenberg T, Schink T, et al. A randomized trial of botulinum toxin A for treatment of drooling. Neurology 2003; 61:1279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verma A, Steele J. Botulinum toxin improves sialorrhea and quality of living in bulbar amyotrophic lateral sclerosis. Muscle Nerve 2006; 34:235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stone CA, O'Leary N. Systematic review of the effectiveness of botulinum toxin or radiotherapy for sialorrhea in patients with amyotrophic lateral sclerosis. J Pain Symptom Manage 2009; 37:246.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jackson CE, Gronseth G, Rosenfeld J, et al. Randomized double-blind study of botulinum toxin type B for sialorrhea in ALS patients. Muscle Nerve 2009; 39:137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Young CA, Ellis C, Johnson J, et al. Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis. Cochrane Database Syst Rev 2011; :CD006981.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Isaacson SH, Ondo W, Jackson CE, et al. Safety and Efficacy of RimabotulinumtoxinB for Treatment of Sialorrhea in Adults: A Randomized Clinical Trial. JAMA Neurol 2020; 77:461.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tuite PJ, Lang AE. Severe and prolonged dysphagia complicating botulinum toxin A injections for dystonia in Machado-Joseph disease. Neurology 1996; 46:846.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harriman M, Morrison M, Hay J, et al. Use of radiotherapy for control of sialorrhea in patients with amyotrophic lateral sclerosis. J Otolaryngol 2001; 30:242.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andersen PM, Grönberg H, Franzen L, Funegård U. External radiation of the parotid glands significantly reduces drooling in patients with motor neurone disease with bulbar paresis. J Neurol Sci 2001; 191:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neppelberg E, Haugen DF, Thorsen L, Tysnes OB. Radiotherapy reduces sialorrhea in amyotrophic lateral sclerosis. Eur J Neurol 2007; 14:1373.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen JH, Wu SC, Chen HJ, et al. Risk of developing pressure sore in amyotrophic lateral sclerosis patients - a nationwide cohort study. J Eur Acad Dermatol Venereol 2018; 32:1589.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brettschneider J, Kurent J, Ludolph A. Drug therapy for pain in amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database Syst Rev 2013; :CD005226.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Newrick PG, Langton-Hewer R. Pain in motor neuron disease. J Neurol Neurosurg Psychiatry 1985; 48:838.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chiò A, Mora G, Lauria G. Pain in amyotrophic lateral sclerosis. Lancet Neurol 2017; 16:144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosen HJ, Cummings J. A real reason for patients with pseudobulbar affect to smile. Ann Neurol 2007; 61:92.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller A, Pratt H, Schiffer RB. Pseudobulbar affect: the spectrum of clinical presentations, etiologies and treatments. Expert Rev Neurother 2011; 11:1077.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parvizi J, Coburn KL, Shillcutt SD, et al. Neuroanatomy of pathological laughing and crying: a report of the American Neuropsychiatric Association Committee on Research. J Neuropsychiatry Clin Neurosci 2009; 21:75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cummings JL, Gilbart J, Andersen G. Pseudobulbar Affect – A Disabling but Under-recognised Consequence of Neurological Disease and Brain Injury. Eur Neurol Rev 2013; 8:74.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gallagher JP. Pathologic laughter and crying in ALS: a search for their origin. Acta Neurol Scand 1989; 80:114.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahmed A, Simmons Z. Pseudobulbar affect: prevalence and management. Ther Clin Risk Manag 2013; 9:483.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schiffer RB, Herndon RM, Rudick RA. Treatment of pathologic laughing and weeping with amitriptyline. N Engl J Med 1985; 312:1480.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iannaccone S, Ferini-Strambi L. Pharmacologic treatment of emotional lability. Clin Neuropharmacol 1996; 19:532.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brooks BR, Thisted RA, Appel SH, et al. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial. Neurology 2004; 63:1364.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pioro EP, Brooks BR, Cummings J, et al. Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect. Ann Neurol 2010; 68:693.
          </a>
         </li>
         <li class="breakAll">
          FDA approval letter (dextromethorphan hydrobromide and quinidine sulfate) https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2010/021879s000ltr.pdf.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klein M, Musacchio JM. High affinity dextromethorphan binding sites in guinea pig brain. Effect of sigma ligands and other agents. J Pharmacol Exp Ther 1989; 251:207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tortella FC, Pellicano M, Bowery NG. Dextromethorphan and neuromodulation: old drug coughs up new activities. Trends Pharmacol Sci 1989; 10:501.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hildebrand M, Seifert W, Reichenberger A. Determination of dextromethorphan metabolizer phenotype in healthy volunteers. Eur J Clin Pharmacol 1989; 36:315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schadel M, Wu D, Otton SV, et al. Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition. J Clin Psychopharmacol 1995; 15:263.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang Y, Britto MR, Valderhaug KL, et al. Dextromethorphan: enhancing its systemic availability by way of low-dose quinidine-mediated inhibition of cytochrome P4502D6. Clin Pharmacol Ther 1992; 51:647.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pioro EP. Current concepts in the pharmacotherapy of pseudobulbar affect. Drugs 2011; 71:1193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hackett ML, Yang M, Anderson CS, et al. Pharmaceutical interventions for emotionalism after stroke. Cochrane Database Syst Rev 2010; :CD003690.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ringholz GM, Appel SH, Bradshaw M, et al. Prevalence and patterns of cognitive impairment in sporadic ALS. Neurology 2005; 65:586.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lomen-Hoerth C, Murphy J, Langmore S, et al. Are amyotrophic lateral sclerosis patients cognitively normal? Neurology 2003; 60:1094.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simmons Z, Bremer BA, Robbins RA, et al. Quality of life in ALS depends on factors other than strength and physical function. Neurology 2000; 55:388.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldstein LH, Atkins L, Landau S, et al. Longitudinal predictors of psychological distress and self-esteem in people with ALS. Neurology 2006; 67:1652.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heidari ME, Nadali J, Parouhan A, et al. Prevalence of depression among amyotrophic lateral sclerosis (ALS) patients: A systematic review and meta-analysis. J Affect Disord 2021; 287:182.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thakore NJ, Pioro EP. Depression in ALS in a large self-reporting cohort. Neurology 2016; 86:1031.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Averill AJ, Kasarskis EJ, Segerstrom SC. Psychological health in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2007; 8:243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reeves WC, Strine TW, Pratt LA, et al. Mental illness surveillance among adults in the United States. MMWR Suppl 2011; 60:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Albert SM, Rabkin JG, Del Bene ML, et al. Wish to die in end-stage ALS. Neurology 2005; 65:68.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McDonald ER, Wiedenfeld SA, Hillel A, et al. Survival in amyotrophic lateral sclerosis. The role of psychological factors. Arch Neurol 1994; 51:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vrijsen B, Buyse B, Belge C, et al. Noninvasive ventilation improves sleep in amyotrophic lateral sclerosis: a prospective polysomnographic study. J Clin Sleep Med 2015; 11:559.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 5129 Version 59.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8423829" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Duration of amyotrophic lateral sclerosis is age dependent.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2608080" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Survival prediction in amyotrophic lateral sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2036615" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Familial amyotrophic lateral sclerosis, 1850-1989: a statistical analysis of the world literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29598923" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30728207" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Development of a prognostic model of respiratory insufficiency or death in amyotrophic lateral sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31322417" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Classifying Patients with Amyotrophic Lateral Sclerosis by Changes in FVC. A Group-based Trajectory Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10227612" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology: ALS Practice Parameters Task Force.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21914052" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)--revised report of an EFNS task force.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19822873" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16247055" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Multidisciplinary ALS care improves quality of life in patients with ALS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17622602" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Palliative care for patients with amyotrophic lateral sclerosis: "prepare for the worst and hope for the best".
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25550416" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : A multidisciplinary clinic approach improves survival in ALS: a comparative study of ALS in Ireland and Northern Ireland.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16614011" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Positive effects of tertiary centres for amyotrophic lateral sclerosis on outcome and use of hospital facilities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12933930" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study, 1996-2000.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17431705" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : ALS multidisciplinary clinic and survival. Results from a population-based study in Southern Italy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26423203" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : A consensus review on the development of palliative care for patients with chronic and progressive neurological disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34583569" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : The Role of Specialty Palliative Care for Amyotrophic Lateral Sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31172537" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Integration of a palliative care specialist in an amyotrophic lateral sclerosis clinic: Observations from one center.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31672715" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Dying of amyotrophic lateral sclerosis: Health care use and cost in the last year of life.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26182947" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Specialist palliative care improves the quality of life in advanced neurodegenerative disorders: NE-PAL, a pilot randomised controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11854102" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Palliative care in amyotrophic lateral sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19822872" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36921894" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Respiratory Management of Patients With Neuromuscular Weakness: An American College of Chest Physicians Clinical Practice Guideline and Expert Panel Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22907221" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Respiratory therapies for amyotrophic lateral sclerosis: a primer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11442324" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Clinical characteristics and management of ALS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30516604" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Critical Care of Neuromuscular Disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30516604" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Critical Care of Neuromuscular Disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12870111" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Warning signs of imminent respiratory failure in neurological patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10589541" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Sniff nasal pressure: a sensitive respiratory test to assess progression of amyotrophic lateral sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11571218" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Respiratory muscle strength and ventilatory failure in amyotrophic lateral sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11029369" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Usefulness of sniff nasal pressure in patients with neuromuscular or skeletal disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15516537" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Use of Sniff nasal-inspiratory force to predict survival in amyotrophic lateral sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35584920" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Comparative Performance of Different Respiratory Test Parameters for Detection of Early Respiratory Insufficiency in Patients With ALS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25202033" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Palliative Care Issues in Amyotrophic Lateral Sclerosis: An Evidenced-Based Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16426990" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28982219" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33799476" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : A Nation-Wide, Multi-Center Study on the Quality of Life of ALS Patients in Germany.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16899545" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Noninvasive positive-pressure ventilation in ALS: predictors of tolerance and survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25857659" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Identifying who will benefit from non-invasive ventilation in amyotrophic lateral sclerosis/motor neurone disease in a clinical cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27197864" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Withdrawal of ventilation at the request of a patient with motor neurone disease: guidance for professionals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28872912" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : An assessment of treatment guidelines, clinical practices, demographics, and progression of disease among patients with amyotrophic lateral sclerosis in Japan, the United States, and Europe.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20660920" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Tracheostomy in amyotrophic lateral sclerosis: a 10-year population-based study in Italy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22214353" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Non-invasive ventilation and gastrostomy may not impact overall quality of life in patients with ALS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23848967" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Weight loss, dysphagia and supplement intake in patients with amyotrophic lateral sclerosis (ALS): impact on quality of life and therapeutic options.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28864675" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Causal inference methods to study gastric tube use in amyotrophic lateral sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31487846" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : A Comprehensive Examination of Percutaneous Endoscopic Gastrostomy and Its Association with Amyotrophic Lateral Sclerosis Patient Outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24582471" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31849093" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Effect of High-Caloric Nutrition on Survival in Amyotrophic Lateral Sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17653917" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Good practice in the management of amyotrophic lateral sclerosis: clinical guidelines. An evidence-based review with good practice points. EALSC Working Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28072907" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Symptomatic treatments for amyotrophic lateral sclerosis/motor neuron disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22871079" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Speech therapy and communication device: impact on quality of life and mood in patients with amyotrophic lateral sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25808635" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Quality of life in amyotrophic lateral sclerosis patients and caregivers: Impact of assistive communication from early stages.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28561886" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Improving symptom management for people with amyotrophic lateral sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29293261" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Treatment of fatigue in amyotrophic lateral sclerosis/motor neuron disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19208404" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Modafinil treatment of fatigue in patients with ALS: a placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26911633" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : A randomized trial of mexiletine in ALS: Safety and effects on muscle cramps and progression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29510461" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Mexiletine for muscle cramps in amyotrophic lateral sclerosis: A randomized, double-blind crossover trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29510461" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Mexiletine for muscle cramps in amyotrophic lateral sclerosis: A randomized, double-blind crossover trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18821142" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Open-label pilot trial of levetiracetam for cramps and spasticity in patients with motor neuron disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22336799" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Treatment for spasticity in amyotrophic lateral sclerosis/motor neuron disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15276195" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31266172" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Botulinum Toxin Type A and Physiotherapy in Spasticity of the Lower Limbs Due to Amyotrophic Lateral Sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30554828" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23728653" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Therapeutic exercise for people with amyotrophic lateral sclerosis or motor neuron disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30230558" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Effects of Strength Training in Amyotrophic Lateral Sclerosis: How Much Do We Know?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10864618" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Injections of botulinum toxin A into the salivary glands improve sialorrhoea in amyotrophic lateral sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14610139" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : A randomized trial of botulinum toxin A for treatment of drooling.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16583370" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Botulinum toxin improves sialorrhea and quality of living in bulbar amyotrophic lateral sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18676117" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Systematic review of the effectiveness of botulinum toxin or radiotherapy for sialorrhea in patients with amyotrophic lateral sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19145653" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Randomized double-blind study of botulinum toxin type B for sialorrhea in ALS patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21563158" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31930364" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Safety and Efficacy of RimabotulinumtoxinB for Treatment of Sialorrhea in Adults: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8618703" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Severe and prolonged dysphagia complicating botulinum toxin A injections for dystonia in Machado-Joseph disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11771037" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Use of radiotherapy for control of sialorrhea in patients with amyotrophic lateral sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11677000" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : External radiation of the parotid glands significantly reduces drooling in patients with motor neurone disease with bulbar paresis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17941851" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Radiotherapy reduces sialorrhea in amyotrophic lateral sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29512203" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Risk of developing pressure sore in amyotrophic lateral sclerosis patients - a nationwide cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23740607" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Drug therapy for pain in amyotrophic lateral sclerosis or motor neuron disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4031936" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Pain in motor neuron disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27964824" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Pain in amyotrophic lateral sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17212357" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : A real reason for patients with pseudobulbar affect to smile.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21539437" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Pseudobulbar affect: the spectrum of clinical presentations, etiologies and treatments.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19359455" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Neuroanatomy of pathological laughing and crying: a report of the American Neuropsychiatric Association Committee on Research.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Pseudobulbar Affect–A Disabling but Under-recognised Consequence of Neurological Disease and Brain Injury
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2816272" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Pathologic laughter and crying in ALS: a search for their origin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24348042" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Pseudobulbar affect: prevalence and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3887172" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Treatment of pathologic laughing and weeping with amitriptyline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8937793" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Pharmacologic treatment of emotional lability.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15505150" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20839238" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20839238" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2477524" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : High affinity dextromethorphan binding sites in guinea pig brain. Effect of sigma ligands and other agents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2694543" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Dextromethorphan and neuromodulation: old drug coughs up new activities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2744072" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Determination of dextromethorphan metabolizer phenotype in healthy volunteers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7593709" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1611804" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Dextromethorphan: enhancing its systemic availability by way of low-dose quinidine-mediated inhibition of cytochrome P4502D6.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21711063" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Current concepts in the pharmacotherapy of pseudobulbar affect.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20166068" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Pharmaceutical interventions for emotionalism after stroke.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16116120" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Prevalence and patterns of cognitive impairment in sporadic ALS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12682312" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Are amyotrophic lateral sclerosis patients cognitively normal?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10932273" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Quality of life in ALS depends on factors other than strength and physical function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17101899" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Longitudinal predictors of psychological distress and self-esteem in people with ALS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33799036" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Prevalence of depression among amyotrophic lateral sclerosis (ALS) patients: A systematic review and meta-analysis
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26888995" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Depression in ALS in a large self-reporting cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17653923" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Psychological health in patients with amyotrophic lateral sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21881550" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Mental illness surveillance among adults in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16009887" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Wish to die in end-stage ALS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8274106" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Survival in amyotrophic lateral sclerosis. The role of psychological factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25766713" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Noninvasive ventilation improves sleep in amyotrophic lateral sclerosis: a prospective polysomnographic study.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
